News briefing: Pfizer on track to early '22 pivotal readout on hemophilia A; Codiak scales back IPO expectations
Pfizer and Sangamo have dosed their first patient in the Phase III gene therapy trial of giroctocogene fitelparvovec (SB-525) for hemophilia A. Researchers will be following the experiences of patients for 12 months after dose, checking on safety, efficacy and durability. The move comes on the heels of a major setback at rival BioMarin, which received a rejection letter from the FDA, which demanded more proof of durability — a sore point among some of the analysts tracking the program.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters